WO2007076161A3 - Compounds with therapeutic activity - Google Patents

Compounds with therapeutic activity Download PDF

Info

Publication number
WO2007076161A3
WO2007076161A3 PCT/US2006/049558 US2006049558W WO2007076161A3 WO 2007076161 A3 WO2007076161 A3 WO 2007076161A3 US 2006049558 W US2006049558 W US 2006049558W WO 2007076161 A3 WO2007076161 A3 WO 2007076161A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
therapeutic activity
pharmaceutical compositions
delaying
onset
Prior art date
Application number
PCT/US2006/049558
Other languages
French (fr)
Other versions
WO2007076161A2 (en
Inventor
Ashok C Bajji
Se-Ho Kim
Richard Trovato
Robert J Mchugh
Benjamin Markovitz
Mark B Anderson
Original Assignee
Myriad Genetics Inc
Ashok C Bajji
Se-Ho Kim
Richard Trovato
Robert J Mchugh
Benjamin Markovitz
Mark B Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Ashok C Bajji, Se-Ho Kim, Richard Trovato, Robert J Mchugh, Benjamin Markovitz, Mark B Anderson filed Critical Myriad Genetics Inc
Publication of WO2007076161A2 publication Critical patent/WO2007076161A2/en
Publication of WO2007076161A3 publication Critical patent/WO2007076161A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an oxazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer.
PCT/US2006/049558 2005-12-27 2006-12-27 Compounds with therapeutic activity WO2007076161A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75455905P 2005-12-27 2005-12-27
US60/754,559 2005-12-27

Publications (2)

Publication Number Publication Date
WO2007076161A2 WO2007076161A2 (en) 2007-07-05
WO2007076161A3 true WO2007076161A3 (en) 2007-11-08

Family

ID=38218736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049558 WO2007076161A2 (en) 2005-12-27 2006-12-27 Compounds with therapeutic activity

Country Status (1)

Country Link
WO (1) WO2007076161A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7028766B2 (en) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2178870T1 (en) * 2007-08-17 2018-11-30 Lg Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
JP5328816B2 (en) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー Modulator of amyloid β
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
KR101324414B1 (en) 2008-10-09 2013-11-01 에프. 호프만-라 로슈 아게 Modulators for amyloid beta
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
WO2011000566A2 (en) * 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2012166463A2 (en) 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
JO3225B1 (en) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
CN103992310B (en) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 One group replaces benzo heterocyclic amine derivant and preparation method thereof and the related application as IMPDH inhibitor
TN2016000005A1 (en) * 2013-07-08 2017-07-05 Bayer Pharma AG Substituted pyrazolo-pyridinamines
KR101547885B1 (en) 2014-02-27 2015-08-27 한국화학연구원 Pharmaceutical compositions for cancer prevention or treatment comprising the SIRT7 inhibitor
TW201609719A (en) 2014-05-28 2016-03-16 美國禮來大藥廠 6-substituted-3H-1,3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists
EP3262041A4 (en) * 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2018039539A1 (en) 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
KR102469161B1 (en) 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 ROH-related protein kinase inhibitors, pharmaceutical compositions containing RS-related protein kinase inhibitors, manufacturing methods and uses of pharmaceutical compositions
CN117343049A (en) 2017-06-30 2024-01-05 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
JP2020525525A (en) 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． RHO-related protein kinase inhibitor, pharmaceutical composition containing RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition
CN113736285A (en) * 2020-03-18 2021-12-03 宝天生物科技（上海）有限公司 Ultraviolet light excited fluorescent dye and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282805A1 (en) * 2004-06-15 2005-12-22 Hangeland Jon J Five-membered heterocycles useful as serine protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282805A1 (en) * 2004-06-15 2005-12-22 Hangeland Jon J Five-membered heterocycles useful as serine protease inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7028766B2 (en) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase

Also Published As

Publication number Publication date
WO2007076161A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007076161A3 (en) Compounds with therapeutic activity
WO2009105513A3 (en) Novel compounds and methods for therapy
EP1865967A4 (en) Compounds, compositions and methods for the treatment of viral infections and other medical disorders
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
MX2009004786A (en) Anilinopiperazine derivatives and methods of use thereof.
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
EP1859793A4 (en) Novel combinational use of sulfonamide compound
WO2006030439A3 (en) Compositions and methods for inducing hair growth
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2009011850A3 (en) Novel therapeutic compounds
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007047608A3 (en) Fibrin targeted therapeutics
BRPI0506970B8 (en) alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX2010004876A (en) Diamido thiazole derivatives as protein kinase inhibitors.
WO2006109301A3 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848329

Country of ref document: EP

Kind code of ref document: A2